Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: DEPO
- CUSIP: 24990810
- Previous Close: $16.47
- 50 Day Moving Average: $18.09
- 200 Day Moving Average: $20.66
- 52-Week Range: $12.25 - $27.02
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 13.25
- P/E Growth: 1.00
- Market Cap: $971.12M
- Outstanding Shares: 61,580,000
- Beta: 1.33
- Net Margins: -16.93%
- Return on Equity: -7.49%
- Return on Assets: -1.73%
Companies Related to Depomed:
- Debt-to-Equity Ratio: 2.46%
- Current Ratio: 1.21%
- Quick Ratio: 1.16%
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
Where is Depomed's stock going? Where will Depomed's stock price be in 2017?
11 brokerages have issued 12 month price targets for Depomed's stock. Their forecasts range from $14.00 to $31.00. On average, they anticipate Depomed's share price to reach $22.36 in the next year.
When will Depomed announce their earnings?
Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
What are analysts saying about Depomed stock?
Here are some recent quotes from research analysts about Depomed stock:
Cantor Fitzgerald analysts commented, "Management sees aggressive expansion in the pain specialty as PCPs continue to be uncomfortable in prescribing opioids and referring their pain patients. DEPO is currently doing their 12-18 month sales force reorg, with majority of reps focused on pain specialists with Nucynta, Nucynta ER and Gralise." (1/11/2017)
Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)
Who owns Depomed stock?
Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.64%), Dimensional Fund Advisors LP (2.17%), Oxford Asset Management (1.34%), FMR LLC (1.15%), Alpine Associates Management Inc. (0.93%) and Commonwealth of Pennsylvania Public School Empls Retrmt SYS (0.62%). Company insiders that own Depomed stock include August J Moretti and Thadd M Vargas.
Who sold Depomed stock? Who is selling Depomed stock?
Depomed's stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, Guggenheim Capital LLC, Highland Capital Management LP, TCW Group Inc., Envestnet Asset Management Inc., Ladenburg Thalmann Financial Services Inc. and Teachers Retirement System of The State of Kentucky. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas.
Who bought Depomed stock? Who is buying Depomed stock?
Depomed's stock was bought by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, State Street Corp, FMR LLC, Russell Investments Group Ltd., Levin Capital Strategies L.P., Comerica Bank and Glacier Peak Capital LLC.
How do I buy Depomed stock?
Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Depomed stock cost?
One share of Depomed stock can currently be purchased for approximately $15.77.